Alzheimer's Disease Diagnostic Global Market Report 2025

The alzheimer's disease diagnostic market size has grown rapidly in recent years. It will grow from $6.56 billion in 2024 to $7.28 billion in 2025 at a compound annual growth rate (CAGR) of 11%. The growth during the historic period can be attributed to the rising prevalence of Alzheimer’s disease and dementia, increasing awareness of the importance of early diagnosis for better management, advancements in imaging technologies such as MRI and PET scans, growing investment in research and development for neurodegenerative diseases, and government initiatives and funding for Alzheimer’s research and diagnostics.

The alzheimer's disease diagnostic market size is expected to see rapid growth in the next few years. It will grow to $10.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the development of blood-based biomarkers for non-invasive diagnosis, increasing demand for personalized medicine and precision diagnostics, the integration of AI and machine learning in diagnostic tools for early detection, the growing adoption of digital health technologies for remote monitoring and diagnosis, and the expansion of healthcare infrastructure in emerging markets to improve accessibility. Key trends expected during this period include the emergence of multi-modal diagnostic approaches combining imaging, biomarkers, and cognitive tests, a rising focus on point-of-care diagnostic solutions for faster results, the development of wearable devices for continuous monitoring of cognitive health, increased collaborations between biotech companies and research institutions for innovative solutions, and the growth of direct-to-consumer genetic testing for Alzheimer’s risk assessment.

The rise in chronic diseases is anticipated to drive the growth of the Alzheimer’s disease diagnostic market. Chronic disease refers to a long-term health condition that persists for more than three months. The increasing prevalence of chronic diseases is influenced by several interconnected factors, including lifestyle choices, environmental factors, genetic predisposition, and socioeconomic conditions. The presence of chronic conditions such as cardiovascular issues, diabetes, and hypertension elevates the risk of developing Alzheimer's disease (AD) and other forms of dementia. For example, in January 2022, a report by the American Heart Association Inc., a US-based nonprofit voluntary organization, stated that brain disorders in the US are expected to increase to 9.3 million by 2060, with the number currently growing. Additionally, one in every six people worldwide suffers from a brain disease, and by 2021, approximately 1 billion people globally were affected by brain disorders. As a result, the increasing prevalence of chronic diseases is expected to drive the growth of the Alzheimer’s disease diagnostic market.

Leading companies in the Alzheimer’s disease diagnostic market are prioritizing advancements in blood-based biomarker tests, which are expected to streamline the diagnostic process for Alzheimer's disease. These advancements aim to reduce dependence on more invasive procedures and enhance access to timely treatment for patients. For example, in October 2023, Quanterix, a US-based biotechnology research company, introduced the LucentAD p-Tau 217 test, a biomarker for Alzheimer's pathology that offers high clinical sensitivity and specificity in blood testing. Traditional methods for cerebrospinal fluid (CSF) biomarker analysis involve positron emission tomography (PET) scans or lumbar punctures, both of which are costly, invasive, and not widely accessible. The new test integrates Quanterix's ultra-sensitive SimoaÒ technology with J&J Innovative Medicine's extensively tested p-Tau 217 antibodies, ensuring high accuracy and a more straightforward diagnostic process.

In July 2024, Lantheus, a US-based radiopharmaceutical company, acquired Meilleur Technologies for an undisclosed amount. This acquisition is aimed at expanding Lantheus’ portfolio of PET imaging agents for Alzheimer’s disease. Meilleur Technologies, a US-based biopharmaceutical company, has collaborated with research institutions to develop imaging biomarkers for Alzheimer’s disease.

Major players in the alzheimer’s disease diagnostic market are Pfizer Inc., AbbVie, Bristol Myers Squibb Company, Hoffmann-La Roche, Eli Lilly and Company, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Daiichi Sankyo Co., Sysmex, Lantheus, Quanterix, FujireBio, TauRx Pharmaceuticals Ltd, AC Immune, C2N diagnostics, AXON Neuroscience, Neuro-Bio Ltd, Anavex Life Sciences Corp., and Treventis Corporation.

North America was the largest region in the alzheimer's disease diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in alzheimer's disease diagnostic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the alzheimer's disease diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Alzheimer’s disease diagnostics involve methods and tools used to detect and confirm the presence of Alzheimer’s, a progressive neurodegenerative disorder. These diagnostics include cognitive assessments, imaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, and biomarker tests that analyze cerebrospinal fluid (CSF) or blood for amyloid-beta and tau proteins.

The primary types of Alzheimer’s disease diagnostics include triage, diagnosis, and screening. Triage is a systematic method for prioritizing patients based on the urgency and severity of their cognitive symptoms. Diagnostic techniques encompass biomarkers, imaging techniques, genetic testing, and cognitive assessment tests. These are utilized by various end users, including clinics, hospitals, diagnostic centers, pharmaceutical companies, and academic research centers.

The alzheimer’s disease diagnostic market research report is one of a series of new reports that provides alzheimer’s disease diagnostic market statistics, including alzheimer’s disease diagnostic industry global market size, regional shares, competitors with a alzheimer’s disease diagnostic market share, detailed alzheimer’s disease diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer’s disease diagnostic industry. This alzheimer’s disease diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The alzheimer's disease diagnostic market consists of revenues earned by entities by providing services such as cognitive assessment tests, genetic tests, biomarker tests, and cerebrospinal fluid analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The alzheimer's disease diagnostic market also includes sales of genetic testing kits, cognitive assessment tools, imaging equipment, biomarker kits, and wearable devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.